Spain’s pharmaceutical R&D spending dropped 5.3% to €974 million ($1.3 billion) in 2011, which is the lowest amount since 2007. In 2010, pharmaceutical R&D spending increased 6.5% to €1.0 billion. Spending on clinical trials accounted for 48% of R&D spending, and basic research represented 14%. Fourteen percent of pharmaceutical R&D spending in 2011 was for basic research. Internal R&D spending and external R&D spending, which consists of research contracts with hospitals, universities, and public facilities, accounted for 57% and 43% of spending, respectively. Spending on biotechnology was one-fifth of pharmaceutical R&D spending, or nearly €200 million. The number of R&D personnel at drug companies in Spain dropped 4.2% to 4,490 last year, the lowest since 2006.

Source: Farmaindustria